Apogee Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
APGE Nasdaq 2834 www.apogeetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apogee Therapeutics, Inc.

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Feb 5th, 2026 6:00 am
Elastic NV, Acadia Healthcare, and More Stocks See Action From Activist Investors - Jan 30th, 2026 5:39 pm
Funding for Risky Biotechs Is Returning - Jan 12th, 2026 10:00 am
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - Jan 11th, 2026 11:03 am
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 1b Asthma Trial Data And 2026 Pipeline Milestones - Jan 11th, 2026 5:09 am
Positive Asthma Data and I&I Pipeline Plans Could Be A Game Changer For Apogee Therapeutics (APGE) - Jan 10th, 2026 8:11 pm
Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally - Jan 7th, 2026 4:17 pm
Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls - Jan 7th, 2026 7:41 am
Apogee Says Interim Trial Results of Zumilokibart in Asthma Show Fast, Durable Suppression of Inflammation - Jan 6th, 2026 5:10 am
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook - Jan 6th, 2026 4:00 am
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 - Jan 5th, 2026 2:01 pm
Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth - Dec 9th, 2025 12:19 am
Assessing Apogee Therapeutics (APGE) Valuation After Recent Surge in Investor Interest - Nov 15th, 2025 5:18 pm
Why Apogee Therapeutics (APGE) Is Up 19.7% After Strong APG333 Trial Data and Cash Infusion - Nov 15th, 2025 4:08 pm
Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? - Nov 11th, 2025 7:40 am
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine - Nov 11th, 2025 6:00 am
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results - Nov 10th, 2025 5:10 am
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody - Nov 10th, 2025 5:00 am
Apogee Therapeutics to Participate in Upcoming Conferences - Nov 3rd, 2025 5:30 am
Why Apogee Therapeutics (APGE) Is Up 6.1% After $300 Million Raise to Advance APG777 - Oct 31st, 2025 5:10 pm